Metastatic Breast Cancer (mBC) Patient Educational Events
ESR1 Mutations in mBC: Should I Get Tested?
Nearly 1 out of 2 people living with ER+/HER2- mBC may develop an ESR1 mutation after progression on hormone therapy.
Engage with a community of individuals like you where you’ll learn about how your mBC may change over time. You’ll also hear about the importance of testing for the ESR1 mutation from a metastatic breast cancer expert, and a real patient/caregiver story.
NEXT EVENT: [Date]
Thanks!
*Speakers are paid consultants by Stemline Therapeutics, Inc.